Syndax Pharmaceuticals
SNDX
SNDX
227 hedge funds and large institutions have $2.1B invested in Syndax Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 83 increasing their positions, 79 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
5% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 79
0% more funds holding
Funds holding: 227 → 227 (0)
2.49% less ownership
Funds ownership: 117.4% → 114.91% (-2.5%)
Holders
227
Holding in Top 10
11
Calls
$30M
Puts
$14.4M
Top Buyers
| 1 | +$40.4M | |
| 2 | +$19M | |
| 3 | +$17.7M | |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$13.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13M |
Top Sellers
| 1 | -$51M | |
| 2 | -$30.4M | |
| 3 | -$17.3M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$16.7M |
